Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024 ...

Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen posted earnings that were better than expected last month. Because Amgen stock has heavy institutional ownership, this ...

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Sudden cardiac arrest and death occur among competitive and recreational athletes across the entire spectrum of age, sex, and ...

Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...

We are grateful to our colleagues for their interest and thoughtful comments on our Seminar about systemic lupus erythematosus (SLE).1 We appreciate the remarks from Qihe Xu, and Thomas Pabst and ...

Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...

More than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t generate much sales momentum behind the product. Its latest gambit is ...

Digital preservation is not keeping up with the growth of scholarly knowledge. Recognizing its causes is the first step to securing records everywhere for future generations. At the interface ...